Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Sep 17;12(3):709-714.
doi: 10.1159/000502858. eCollection 2019 Sep-Dec.

Unexpected Response to Nivolumab in a "Fast Progressor" Head and Neck Cancer Patient

Martina Napolitano  1 , Lucia Trudu  1 , Federica Bertolini  1
Affiliations
Case Reports

Unexpected Response to Nivolumab in a "Fast Progressor" Head and Neck Cancer Patient

Martina Napolitano et al. Case Rep Oncol. .

Abstract

Prior to the advent of immune checkpoint inhibitors targeting PD-1/PD-L1 axis no drug demonstrated to improve survival or quality of life in the second-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). Nivolumab appear to have a clear clinical benefit for R/M-HNSCC, based on improved survival, good toxicity profile, reduction in symptoms and improvement in overall quality of life. This benefit seems to be greater for PD-L1 positive patients and independent of previous treatment, even being observed among heavily pre-treated patients. However, even in responding tumors acquired resistance to nivolumab usually occurred, limiting the drug's activity. We report a case of unexpected prolonged stable disease in second-line treatment with nivolumab after a rapid progression disease under first-line chemotherapy in biomarker-positive R/M-HNSCC.

Keywords: HNSCC; Head and neck cancer; Mixed response; Nivolumab; PD-L1.

PubMed Disclaimer

Conflict of interest statement

The authors certify that they have no conflicts of interest to disclose in the subject matter discussed in this paper.

References

    1. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep;359((11)):1116–27. - PubMed
    1. Ferris RL, Blumenschein G, Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov;375((19)):1856–67. - PMC - PubMed
    1. Ferris RL, Blumenschein G, Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018 Jun;81:45–51. - PMC - PubMed
    1. Ferris RL, Blumenschein G, Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: analyses from CheckMate 141. Proc. Am. Assoc. Cancer Res. 2017;77((Suppl. 13)) Abstract nr CT021.
    1. van der Velden JM, van der Linden YM, Versteeg AL, Verlaan JJ, Sophie Gerlich A, Pielkenrood BJ, et al. Evaluation of effectiveness of palliative radiotherapy for bone metastases: a prospective cohort study. J Radiat Oncol. 2018;7((4)):325–33. - PMC - PubMed

Publication types